Orphan Receptor GPR88 as an Emerging Neurotherapeutic Target

Na Ye, Bang Li, Qi Mao, Eric A. Wold, Sheng Tian, John Allen, Jia Zhou

Research output: Contribution to journalReview article

Abstract

Although G protein-coupled receptors (GPCRs) are recognized as pivotal drug targets involved in multiple physiological and pathological processes, the majority of GPCRs including orphan GPCRs (oGPCRs) are unexploited. GPR88, a brain-specific oGPCR with particularly robust expression in the striatum, regulates diverse brain and behavioral functions, including cognition, mood, movement control, and reward-based learning, and is thus emerging as a novel drug target for central nervous system disorders including schizophrenia, Parkinson's disease, anxiety, and addiction. Nevertheless, no effective GPR88 synthetic ligands have yet entered into clinical trials, and GPR88 endogenous ligands remain unknown. Despite the recent discovery and early stage study of several GPR88 agonists, such as 2-PCCA, RTI-13951-33, and phenylglycinol derivatives, further research into GPR88 pharmacology, medicinal chemistry, and chemical biology is urgently needed to yield structurally diversified GPR88-specific ligands. Drug-like pharmacological tool function and relevant signaling elucidation will also accelerate the evaluation of this receptor as a viable neurotherapeutic target.

Original languageEnglish (US)
Article number10.1021/acschemneuro.8b00572
Pages (from-to)190-200
Number of pages11
JournalACS Chemical Neuroscience
Volume10
Issue number1
DOIs
StatePublished - Jan 16 2019

Fingerprint

G-Protein-Coupled Receptors
Ligands
Brain
Pharmaceutical Preparations
Pharmacology
Physiological Phenomena
Pharmaceutical Chemistry
Central Nervous System Diseases
Neurology
Pathologic Processes
Reward
Cognition
Parkinson Disease
Schizophrenia
Anxiety
Clinical Trials
Learning
Derivatives
Research

Keywords

  • agonists
  • CNS disorders
  • drug discovery
  • GPR88
  • neurotherapeutics
  • Orphan G protein-coupled receptors (oGPCRs)
  • striatum

ASJC Scopus subject areas

  • Biochemistry
  • Physiology
  • Cognitive Neuroscience
  • Cell Biology

Cite this

Ye, N., Li, B., Mao, Q., Wold, E. A., Tian, S., Allen, J., & Zhou, J. (2019). Orphan Receptor GPR88 as an Emerging Neurotherapeutic Target. ACS Chemical Neuroscience, 10(1), 190-200. [10.1021/acschemneuro.8b00572]. https://doi.org/10.1021/acschemneuro.8b00572

Orphan Receptor GPR88 as an Emerging Neurotherapeutic Target. / Ye, Na; Li, Bang; Mao, Qi; Wold, Eric A.; Tian, Sheng; Allen, John; Zhou, Jia.

In: ACS Chemical Neuroscience, Vol. 10, No. 1, 10.1021/acschemneuro.8b00572, 16.01.2019, p. 190-200.

Research output: Contribution to journalReview article

Ye, N, Li, B, Mao, Q, Wold, EA, Tian, S, Allen, J & Zhou, J 2019, 'Orphan Receptor GPR88 as an Emerging Neurotherapeutic Target', ACS Chemical Neuroscience, vol. 10, no. 1, 10.1021/acschemneuro.8b00572, pp. 190-200. https://doi.org/10.1021/acschemneuro.8b00572
Ye N, Li B, Mao Q, Wold EA, Tian S, Allen J et al. Orphan Receptor GPR88 as an Emerging Neurotherapeutic Target. ACS Chemical Neuroscience. 2019 Jan 16;10(1):190-200. 10.1021/acschemneuro.8b00572. https://doi.org/10.1021/acschemneuro.8b00572
Ye, Na ; Li, Bang ; Mao, Qi ; Wold, Eric A. ; Tian, Sheng ; Allen, John ; Zhou, Jia. / Orphan Receptor GPR88 as an Emerging Neurotherapeutic Target. In: ACS Chemical Neuroscience. 2019 ; Vol. 10, No. 1. pp. 190-200.
@article{77af57ad49e6417bb3c80d48d4676a7f,
title = "Orphan Receptor GPR88 as an Emerging Neurotherapeutic Target",
abstract = "Although G protein-coupled receptors (GPCRs) are recognized as pivotal drug targets involved in multiple physiological and pathological processes, the majority of GPCRs including orphan GPCRs (oGPCRs) are unexploited. GPR88, a brain-specific oGPCR with particularly robust expression in the striatum, regulates diverse brain and behavioral functions, including cognition, mood, movement control, and reward-based learning, and is thus emerging as a novel drug target for central nervous system disorders including schizophrenia, Parkinson's disease, anxiety, and addiction. Nevertheless, no effective GPR88 synthetic ligands have yet entered into clinical trials, and GPR88 endogenous ligands remain unknown. Despite the recent discovery and early stage study of several GPR88 agonists, such as 2-PCCA, RTI-13951-33, and phenylglycinol derivatives, further research into GPR88 pharmacology, medicinal chemistry, and chemical biology is urgently needed to yield structurally diversified GPR88-specific ligands. Drug-like pharmacological tool function and relevant signaling elucidation will also accelerate the evaluation of this receptor as a viable neurotherapeutic target.",
keywords = "agonists, CNS disorders, drug discovery, GPR88, neurotherapeutics, Orphan G protein-coupled receptors (oGPCRs), striatum",
author = "Na Ye and Bang Li and Qi Mao and Wold, {Eric A.} and Sheng Tian and John Allen and Jia Zhou",
year = "2019",
month = "1",
day = "16",
doi = "10.1021/acschemneuro.8b00572",
language = "English (US)",
volume = "10",
pages = "190--200",
journal = "ACS Chemical Neuroscience",
issn = "1948-7193",
publisher = "American Chemical Society",
number = "1",

}

TY - JOUR

T1 - Orphan Receptor GPR88 as an Emerging Neurotherapeutic Target

AU - Ye, Na

AU - Li, Bang

AU - Mao, Qi

AU - Wold, Eric A.

AU - Tian, Sheng

AU - Allen, John

AU - Zhou, Jia

PY - 2019/1/16

Y1 - 2019/1/16

N2 - Although G protein-coupled receptors (GPCRs) are recognized as pivotal drug targets involved in multiple physiological and pathological processes, the majority of GPCRs including orphan GPCRs (oGPCRs) are unexploited. GPR88, a brain-specific oGPCR with particularly robust expression in the striatum, regulates diverse brain and behavioral functions, including cognition, mood, movement control, and reward-based learning, and is thus emerging as a novel drug target for central nervous system disorders including schizophrenia, Parkinson's disease, anxiety, and addiction. Nevertheless, no effective GPR88 synthetic ligands have yet entered into clinical trials, and GPR88 endogenous ligands remain unknown. Despite the recent discovery and early stage study of several GPR88 agonists, such as 2-PCCA, RTI-13951-33, and phenylglycinol derivatives, further research into GPR88 pharmacology, medicinal chemistry, and chemical biology is urgently needed to yield structurally diversified GPR88-specific ligands. Drug-like pharmacological tool function and relevant signaling elucidation will also accelerate the evaluation of this receptor as a viable neurotherapeutic target.

AB - Although G protein-coupled receptors (GPCRs) are recognized as pivotal drug targets involved in multiple physiological and pathological processes, the majority of GPCRs including orphan GPCRs (oGPCRs) are unexploited. GPR88, a brain-specific oGPCR with particularly robust expression in the striatum, regulates diverse brain and behavioral functions, including cognition, mood, movement control, and reward-based learning, and is thus emerging as a novel drug target for central nervous system disorders including schizophrenia, Parkinson's disease, anxiety, and addiction. Nevertheless, no effective GPR88 synthetic ligands have yet entered into clinical trials, and GPR88 endogenous ligands remain unknown. Despite the recent discovery and early stage study of several GPR88 agonists, such as 2-PCCA, RTI-13951-33, and phenylglycinol derivatives, further research into GPR88 pharmacology, medicinal chemistry, and chemical biology is urgently needed to yield structurally diversified GPR88-specific ligands. Drug-like pharmacological tool function and relevant signaling elucidation will also accelerate the evaluation of this receptor as a viable neurotherapeutic target.

KW - agonists

KW - CNS disorders

KW - drug discovery

KW - GPR88

KW - neurotherapeutics

KW - Orphan G protein-coupled receptors (oGPCRs)

KW - striatum

UR - http://www.scopus.com/inward/record.url?scp=85060169523&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85060169523&partnerID=8YFLogxK

U2 - 10.1021/acschemneuro.8b00572

DO - 10.1021/acschemneuro.8b00572

M3 - Review article

VL - 10

SP - 190

EP - 200

JO - ACS Chemical Neuroscience

JF - ACS Chemical Neuroscience

SN - 1948-7193

IS - 1

M1 - 10.1021/acschemneuro.8b00572

ER -